Description
The adriamycin-resistant cell line A2780ADR has been developed by exposure of the parent A2780 cell line to adriamycin. A2780ADR is cross-resistant to melphalan and vinblastine. To retain resistance adriamycin has to be added to the media. The cells grow as a monolayer and in suspension in spinner cultures and are tumourigenic in immune deficient mice. Together with the cisplatin-resistant variant A2780cis these lines only differ in their exposure to a single drug and should facilitate the search for molecular changes responsible for the expression of pleiotropic drug resistance in human ovarian cancer.
Adherent Suspension
Adherent
Suggested Medium
RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS); treatment with 10E-7 M adriamycin at least once a week.
Quality Control
A2780ADR Cell Line was tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Shippment
A2780ADR Cell Line will be shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
A2780ADR Cell Line is for research use only
